TERT promoter mutation analysis for blood-based diagnosis and monitoring of gliomas
Abstract Liquid biopsy offers a minimally invasive tool to diagnose and monitor the heterogeneous molecular landscape of tumors over time and therapy. Gliomas have been challenging to sample with blood-based liquid biopsy due to low levels of circulating tumor-derived nucleic acid, and prior efforts have shown specific point mutations in less than 5% of glioma patients. Detection of TERT promoter mutations (C228T, C250T) in cfDNA has been successful for some systemic cancers but has yet to be demonstrated in gliomas, despite the high prevalence of these mutations in glioma tissue (>60% of all tumors). Here, we developed a novel digital droplet PCR (ddPCR) assay, that incorporates features to improve sensitivity and allows for the simultaneous detection and longitudinal monitoring of two TERT promoter mutations (C228T and C250T) in cfDNA from the plasma of glioma patients. In baseline performance in tumor tissue, (n = 157 samples), the assay had perfect concordance with an independently performed clinical pathology laboratory assessment of TERT promoter mutations in the same tumor samples (95% CI 94%-100%). Extending to matched plasma samples, we detected TERT mutations in both discovery and blinded multi-institution validation cohorts with an overall sensitivity of 62.5% (95% CI 52%-73%) and a specificity of 90% (95% CI 80%-96%) compared to the gold standard tumor tissue-based detection of TERT mutations. Upon longitudinal monitoring in 5 patients, we report that peripheral TERT mutant allele frequency reflects the clinical course of the disease with levels decreasing after surgical intervention and therapy and increasing with tumor progression. Our results demonstrate the feasibility of detecting circulating cfDNA TERT promoter mutations in glioma patients with clinically relevant sensitivity and specificity using a novel, enhanced ddPCR approach. The functionality of this assay also suggests a new clinical role for plasma-based cfDNA analysis to complement tissue-based histopathologic and molecular characterization for diagnosis and spatiotemporal monitoring of brain tumors..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 13. Feb. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Muralidharan, Koushik [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.09.03.20135236 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018690971 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018690971 | ||
| 003 | DE-627 | ||
| 005 | 20230429085321.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200907s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.09.03.20135236 |2 doi | |
| 035 | |a (DE-627)XBI018690971 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.09.03.20135236 | ||
| 035 | |a (biorXiv)10.1101/2020.09.03.20135236 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Muralidharan, Koushik |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TERT promoter mutation analysis for blood-based diagnosis and monitoring of gliomas |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Liquid biopsy offers a minimally invasive tool to diagnose and monitor the heterogeneous molecular landscape of tumors over time and therapy. Gliomas have been challenging to sample with blood-based liquid biopsy due to low levels of circulating tumor-derived nucleic acid, and prior efforts have shown specific point mutations in less than 5% of glioma patients. Detection of TERT promoter mutations (C228T, C250T) in cfDNA has been successful for some systemic cancers but has yet to be demonstrated in gliomas, despite the high prevalence of these mutations in glioma tissue (>60% of all tumors). Here, we developed a novel digital droplet PCR (ddPCR) assay, that incorporates features to improve sensitivity and allows for the simultaneous detection and longitudinal monitoring of two TERT promoter mutations (C228T and C250T) in cfDNA from the plasma of glioma patients. In baseline performance in tumor tissue, (n = 157 samples), the assay had perfect concordance with an independently performed clinical pathology laboratory assessment of TERT promoter mutations in the same tumor samples (95% CI 94%-100%). Extending to matched plasma samples, we detected TERT mutations in both discovery and blinded multi-institution validation cohorts with an overall sensitivity of 62.5% (95% CI 52%-73%) and a specificity of 90% (95% CI 80%-96%) compared to the gold standard tumor tissue-based detection of TERT mutations. Upon longitudinal monitoring in 5 patients, we report that peripheral TERT mutant allele frequency reflects the clinical course of the disease with levels decreasing after surgical intervention and therapy and increasing with tumor progression. Our results demonstrate the feasibility of detecting circulating cfDNA TERT promoter mutations in glioma patients with clinically relevant sensitivity and specificity using a novel, enhanced ddPCR approach. The functionality of this assay also suggests a new clinical role for plasma-based cfDNA analysis to complement tissue-based histopathologic and molecular characterization for diagnosis and spatiotemporal monitoring of brain tumors. | ||
| 700 | 1 | |a Yekula, Anudeep |e verfasserin |4 aut | |
| 700 | 1 | |a Small, Julia L. |e verfasserin |4 aut | |
| 700 | 1 | |a Rosh, Zachary S. |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Keiko M. |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lan |e verfasserin |4 aut | |
| 700 | 1 | |a Lau, Spencer |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hakho |e verfasserin |4 aut | |
| 700 | 1 | |a Bettegowda, Chetan |e verfasserin |4 aut | |
| 700 | 1 | |a Chicoine, Michael R. |e verfasserin |4 aut | |
| 700 | 1 | |a Kalkanis, Steven N. |e verfasserin |4 aut | |
| 700 | 1 | |a Shankar, Ganesh M. |e verfasserin |4 aut | |
| 700 | 1 | |a Nahed, Brian V. |e verfasserin |4 aut | |
| 700 | 1 | |a Curry, William T. |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Pamela S. |e verfasserin |4 aut | |
| 700 | 1 | |a Cahill, Daniel P. |e verfasserin |4 aut | |
| 700 | 1 | |a Balaj, Leonora |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Bob S. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 13. Feb. |
| 773 | 1 | 8 | |g year:2021 |g day:13 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.09.03.20135236 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 13 |c 02 | ||
| 953 | |2 045F |a 570 | ||